| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of chrysophanol-8-O-beta-D-glucopyranoside is elastase, a protease enzyme involved in tissue remodeling and inflammation. The compound has moderate elastase inhibitory activity. Additionally, it has shown anti-diabetic properties and can play metabolic roles in the insulin-stimulated glucose transport pathway. It also exhibits significant anti-HBV activity.
|
|---|---|
| ln Vitro |
In vitro, chrysophanol-8-O-beta-D-glucopyranoside demonstrates moderate elastase inhibitory activity. It exhibits mild cytotoxicity and anti-diabetic properties, playing metabolic roles in the insulin-stimulated glucose transport pathway. The compound also shows significant anti-HBV activities with enhanced HBeAg and HBsAg sero-conversion rates as well as HBV DNA clearance rates in HepG2 2.2.15 cells.
|
| ln Vivo |
In vivo studies on chrysophanol-8-O-beta-D-glucopyranoside have demonstrated anti-HBV activity in DHBV models and patients with chronic hepatitis B, showing improved liver function and enhanced HBV DNA clearance. The compound also exhibits anti-inflammatory and antiplatelet effects based on its traditional use. Further in vivo studies are needed to fully characterize its pharmacological profile.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, chrysophanol-8-O-beta-D-glucopyranoside is tested against elastase. The enzyme is incubated with varying concentrations of the compound and a fluorogenic or chromogenic substrate. Elastase activity is measured by monitoring the release of the fluorescent or chromogenic product. IC₅₀ values are calculated from dose-response curves to determine the inhibitory potency.
|
| Cell Assay |
For in vitro cell-based assays, chrysophanol-8-O-beta-D-glucopyranoside is typically tested on HepG2 2.2.15 cells (HBV-producing cell line). Cells are treated with the compound at various concentrations (typically 1-100 μM) for several days. HBV DNA levels in the culture medium are measured by qPCR. HBeAg and HBsAg levels are measured by ELISA. Cytotoxicity is assessed using MTT assays to determine the therapeutic index.
|
| Animal Protocol |
For in vivo animal experiments, chrysophanol-8-O-beta-D-glucopyranoside has been studied in DHBV (duck hepatitis B virus) models. The compound is administered orally or intraperitoneally to infected animals. Viral load (DHBV DNA) in serum is monitored by qPCR. Liver function parameters (ALT, AST) are measured. Histopathological examination of liver tissues is performed to evaluate efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for chrysophanol-8-O-beta-D-glucopyranoside are limited. As a glycoside anthraquinone with a molecular weight of 416.39 g/mol, it is expected to have moderate oral bioavailability and may undergo deglycosylation in the gastrointestinal tract. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for chrysophanol-8-O-beta-D-glucopyranoside are limited. As an anthraquinone derivative, it may have mild cytotoxicity at high concentrations. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Rhein 8-O-β-D-glucoside is a β-D-glucoside with rhein as its aglycone, linked by a glycosidic bond at the C-8 hydroxyl position. It is a β-D-glucoside and a monohydroxyanthraquinone. Its function is related to that of rhein. Pulmatine has been reported in Rumex nepalensis, Rheum palmatum, and other organisms with relevant data.
Chrysophanol-8-O-beta-D-glucopyranoside is a research-use only compound and has not been approved for clinical applications. It is also known as chrysophanol 8-O-glucoside and大黄酚-8-O-葡萄糖苷 in Chinese. The compound is isolated from Rumex acetosa, rhubarb, and other organisms. Its molecular weight is 416.39 and formula is characterized. It is available from various research chemical suppliers. |
| Molecular Formula |
C21H20O9
|
|---|---|
| Molecular Weight |
416.3781
|
| Exact Mass |
416.11
|
| CAS # |
13241-28-6
|
| PubChem CID |
442731
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
763.2±60.0 °C at 760 mmHg
|
| Flash Point |
272.8±26.4 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.702
|
| LogP |
1.55
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
30
|
| Complexity |
669
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
WMMOMSNMMDMSRB-JNHRPPPUSA-N
|
| InChi Code |
InChI=1S/C21H20O9/c1-8-5-10-14(11(23)6-8)18(26)15-9(16(10)24)3-2-4-12(15)29-21-20(28)19(27)17(25)13(7-22)30-21/h2-6,13,17,19-23,25,27-28H,7H2,1H3/t13-,17-,19+,20-,21-/m1/s1
|
| Chemical Name |
1-hydroxy-3-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~120.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4017 mL | 12.0083 mL | 24.0165 mL | |
| 5 mM | 0.4803 mL | 2.4017 mL | 4.8033 mL | |
| 10 mM | 0.2402 mL | 1.2008 mL | 2.4017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
